← Back to Search

CMR Imaging for Breast Cancer-Related Cardiotoxicity

N/A

Recruiting

Led By Reza Nezafat, Ph.D

Research Sponsored by Beth Israel Deaconess Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have histologic diagnosis of breast carcinoma

Age > 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year after completion of treatment

Awards & highlights

Study Summary

This trial is testing if CMR can detect heart damage caused by breast cancer drugs.

Who is the study for?

This trial is for adults over 18 with breast cancer who are about to start anthracycline-based chemotherapy. They must be able to consent and have a confirmed diagnosis of breast carcinoma. It's not for those with serious illnesses, pregnant or breastfeeding women, or anyone unable to undergo CMR due to poor kidney function.Check my eligibility

What is being tested?

The study is testing the effectiveness of Cardiac Magnetic Resonance Imaging (CMR) in detecting early heart damage from chemotherapy used in treating breast cancer compared to standard Echocardiograms (ECHO).See study design

What are the potential side effects?

There may be minimal side effects related directly to the imaging procedures such as discomfort during the scan or allergic reactions to contrast agents used in CMR.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with breast cancer.

Select...

I am older than 18 years.

Select...

I am receiving anthracycline as part of my cancer treatment.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year after completion of treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year after completion of treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year after completion of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cardiotoxicity

Trial Design

1Treatment groups

Experimental Treatment

Group I: CMR/ECHOExperimental Treatment2 Interventions

Prior to starting chemotherapy treatment, the participant will undergo the following procedures: Cardiac Magnetic Resonance Imaging (CMR) Echocardiogram (ECHO) in patients with no clinically indicated scans Each imaging procedure will be repeated at predetermined times during the protocol Simple blood collection for plasma biomarker analysis

0 / 3Eligibility criteria met